Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B

Trial Profile

Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Birinapant (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 08 May 2015 According to a TetraLogic Pharmaceuticals media release, enrolment has been temporarily halted due to cranial nerve palsies observed in the first cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top